New Two-Pronged antibody tested to shrink tumors before stomach cancer surgery
NCT ID NCT07273981
Summary
This study is testing whether a new drug called zanidatamab, when combined with standard chemotherapy, can shrink tumors in patients with a specific type of stomach or gastroesophageal junction (GEJ) cancer before they have surgery. The trial will enroll about 30 adults with locally advanced cancer that tests positive for a protein called HER2. Researchers want to see if this combination is safe and effective at reducing the amount of cancer found in the tissue removed during surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.